Global Neuroblastoma Clinical Trials Review 2014 - Analysis of 9 Companies
M2 - Wed Apr 16, 10:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hfcrvd/neuroblastoma) has announced the addition of the "Neuroblastoma Global Clinical Trials Review, H1, 2014" report to their offering. Neuroblastoma Global Clinical Trials Review, H1, 2014" provides data on the Neuroblastoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroblastoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroblastoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Neuroblastoma Therapeutics Clinical Trials - Progenics Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - APEIRON Biologics AG - United Therapeutics Corporation - Cancer Prevention Pharmaceuticals, Inc. - MabVax Therapeutics, Inc. - Eli Lilly and Company - Celgene Corporation - Biotec Pharmacon ASA For more information visit http://www.researchandmarkets.com/research/hf...roblastoma
Global Neuroendocrine Cancer Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mssxcd/neuroendocrine) has announced the addition of the "Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014" provides data on the Neuroendocrine Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroendocrine Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroendocrine Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Institutions - Novartis AG - Pfizer Inc. - Ipsen S.A. - F. Hoffmann-La Roche Ltd. - Progenics Pharmaceuticals, Inc. - Tekmira Pharmaceuticals Corp. - Threshold Pharmaceuticals, Inc. - Merck & Co., Inc. - Eli Lilly and Company - Daiichi Sankyo Company, Limited - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Stanford University - Grupo Espanol de Tumores Neuroendocrinos - University of Wisconsin Madison - The University of Iowa - University of California, San Francisco - Alberta Health Services Visit http://www.researchandmarkets.com/research/ms...oendocrine
Progenics Pharmaceuticals CEO, Mark R. Baker, to Present at 13th Annual Needham Healthcare Conference
GlobeNewswire - Mon Apr 07, 11:00AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
Progenics Pharmaceuticals and Centre for Probe Development and Commercialization Announce Agreement to Manufacture Targeted Radiotherapeutic Candidate for Ultra-Orphan Indications
GlobeNewswire - Tue Apr 01, 11:36AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
Lawsuits, Clinical Studies, Financial Results, and Stock Movements - Analyst Notes on Idenix, BG Medicine, Progenics, Omeros, and Opexa
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), BG Medicine, Inc. (NASDAQ: BGMD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Omeros Corporation (NASDAQ: OMER), and Opexa Therapeutics, Inc. (NASDAQ: OPXA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register http://www.analystsreview.com/register
Progenics Pharmaceuticals (PGNX): An Off-the-Radar Potential Winner - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:42AM CDT
Progenics Pharma looks well positioned for a solid gain, but has been overlooked by investors lately
Top Gainers Ahead of Market -- Research on Genco Shipping & Trading, Progenics Pharma, Rambus, and Exact Sciences
PR Newswire - Wed Mar 19, 7:05AM CDT
The US markets saw a positive sentiment on Tuesday, March 18, 2014, as the NASDAQ Composite closed at 4,333.31, up 1.25%, the Dow Jones Industrial Average ended the session at 16,336.19, up 0.55% and the S&P 500 edged 0.72% higher to finish the trading session at 1,872.25. During the session, gains in the Information Technology, Health Care, and Energy sectors positively impacted the broader market. A number of stocks saw large movements, including Genco Shipping & Trading Ltd (NYSE: GNK), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Rambus Inc. (NASDAQ: RMBS), and Exact Sciences Corp. (NASDAQ: EXAS). Free technical research on GNK, PGNX, RMBS, and EXAS can be downloaded upon signing up at:
Traders Get Bullish on Shares of Progenics Pharmaceuticals, Shares Up 8.3% (PGNX)
Comtex SmarTrend(R) - Tue Mar 18, 12:46PM CDT
Progenics Pharmaceuticals (NASDAQ
Progenics Q4 Loss Narrower Than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 10:40AM CDT
Progenics posted narrower-than-expected loss in the fourth quarter of 2013
Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2013 Financial Results and Initiates Clinical Development of Small Molecule Targeted Therapeutic
GlobeNewswire - Thu Mar 13, 8:01AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
Stock to Watch: Progenics Pharmaceuticals Up 5.9% (PGNX)
Comtex SmarTrend(R) - Tue Mar 11, 10:41AM CDT
Progenics Pharmaceuticals (NASDAQ
Progenics Pharmaceuticals Sets 4Q and Year-End 2013 Financial Results Call for March 13
GlobeNewswire - Mon Mar 10, 12:48PM CDT
Progenics Pharmaceuticals, Inc., (Nasdaq
Progenics Pharmaceuticals Sets 1Q 2014 Financial Results Call for March 13
GlobeNewswire - Tue Mar 04, 11:00AM CST
Progenics Pharmaceuticals, Inc., (Nasdaq
Progenics to Raise Funds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 11:10AM CST
Progenics to raise funds for research and development (R&D) activities and general corporate purposes
Progenics Pharmaceuticals prices public offering at USD4.60 per share
M2 - Mon Feb 24, 6:12AM CST
US-based medical company Progenics Pharmaceuticals (NasdaqGS
Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Fri Feb 21, 8:00AM CST
Progenics Pharmaceuticals, Inc. (Nasdaq
Progenics Pharmaceuticals to launch public offering of common shares
M2 - Fri Feb 21, 4:31AM CST
US-based oncology medicine specialists Progenics Pharmaceuticals (NasdaqGS
Progenics Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Feb 20, 3:01PM CST
Progenics Pharmaceuticals, Inc. (Nasdaq
Salix's sNDA on Relistor Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 4:40PM CST
Salix Pharmaceuticals announced disappointing news when the U.S. Food and Drug Administration (FDA) postponed the previously scheduled meeting on Mar 10-11 to consider the Supplemental New Drug Application (sNDA) for Relistor.
Progenics Pharmaceuticals CEO, Mark R. Baker, to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 06, 1:30PM CST
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company focused on the development of innovative approaches to targeting and treating cancer, announced today that Mark R. Baker, CEO of Progenics, will present at the 16 Annual BIO CEO & Investor Conference which will be held February 10 and 11 at the Waldorf Astoria Hotel in New York City. The presentation will take place on Monday, February 10 at 3:00 PM EST.